Article Text

Download PDFPDF
6 or 3 months of anticoagulant therapy did not differ for treatment failure in patients with DVT, PE, or both

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with deep vein thrombosis (DVT), pulmonary embolism (PE), or both, what is the optimum duration of oral anticoagulant therapy?

Clinical impact ratings IM/Ambulatory care ★★★★★★☆ Haematology ★★★★★★☆


Embedded ImageDesign:

randomised controlled trial (RCT).

Embedded ImageAllocation:


Embedded ImageBlinding:


Embedded ImageFollow-up period:

1 year.

Embedded ImageSetting:

46 hospitals in the UK.

Embedded ImagePatients:

810 patients ⩾18 years of age (mean age 59 y, 53% men, based on 749 patients) with DVT, PE, or both, who were to receive anticoagulant therapy. Exclusion criteria included DVT or PE in the past 3 years; severe DVT or PE requiring embolectomy or thrombolysis; neoplasia in the past 3 years; polycythaemia, thrombocythaemia, homozygous factor V Leiden, lupus anticoagulant, or deficiency of protein C, protein S, or antithrombin; advanced multiple sclerosis, orthopaedic problems of the lower limbs, or prolonged or continuous immobility for other reasons; allergy to heparin or warfarin; need …

View Full Text


  • * Information provided by author.

  • See glossary.

  • For correspondence: Dr I A Campbell, Llandough Hospital, Cardiff, UK. ian.campbell{at}

  • Sources of funding: Pharmacia.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd